LOXL3 and melanoma: In particular, metastatic lesions in distant lymph nodes were detected in only 4% of mice bearing Loxl3 KO melanomas (1 out of 28 mice) while present in 81% of mice bearing Loxl3 WT melanomas (25 out of 31) (Figure 3C).